Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ
- 1 November 2005
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 1 (3), 299-307
- https://doi.org/10.2174/157339905774574365
Abstract
Only a limited number of treatment options are available for insulin resistance, a major cause of type 2 diabetes (T2D) and the metabolic syndrome. None adequately address the simultaneous defects in lipid and carbohydrate metabolism. Peroxisome proliferator-activated receptors (PPARs) are members of the superfamily of nuclear hormone receptors that function as ligand-activated transcription factors. The PPAR family, which includes pparα, pparγ, and pparδ, are receptors for fatty acids and their metabolites. Consequently, PPARs play a critical physiological role in the regulation of genes involved in glucose, fatty acid, and cholesterol metabolism. pparα and pparγ also mediate antiinflammatory effects, which likely contribute to their anti-atherogenic activities. A number of PPAR agonist drugs are marketed for the treatment of individual aspects of the metabolic syndrome. Dual agonists that target both pparα and pparγ are being developed in an effort to broaden the activities and beneficial effects of the ligands selective for pparγ. To address the multiple metabolic defects associated with insulin resistance, T2D and the metabolic syndrome, the simultaneous activation of pparα, pparγ, and pparδ by a single compound (i.e. a PPAR pan-agonist) is being pursued. Similar to pparα and pparγ, pparδ plays a significant role in the regulation of genes that control lipid metabolism. Unlike pparγ, pparδ is not adipogenic, and activation of pparδ is associated with an anti-obesity and more insulin-sensitive phenotype. While there are no currently marketed drugs known to target pparδ, pre-clinical studies indicate that pparδ agonists increase energy expenditure and elevate plasma high-density lipoprotein (HDL) cholesterol. Recent studies in rodents and primates suggest that a small molecule targeting all three isoforms of PPAR would provide a significantly improved treatment option.Keywords
This publication has 20 references indexed in Scilit:
- Effective treatments for insulin resistance: trim the fat and douse the fireTrends in Endocrinology & Metabolism, 2004
- Peroxisome Proliferator-Activated Receptor-Alpha and Atherosclerosis: From Basic Mechanisms to Clinical ImplicationsJMIR AI, 2004
- Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammationInternational Journal of Obesity, 2003
- Peroxisome proliferator‐activated receptor δ controls muscle development and oxydative capabilityThe FASEB Journal, 2003
- Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscleBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2003
- Peroxisome Proliferator-Activated Receptor (PPAR) α and PPARβ/δ, but not PPARγ, Modulate the Expression of Genes Involved in Cardiac Lipid MetabolismCirculation Research, 2003
- PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?International Journal of Obesity, 2003
- PPARγANDGLUCOSEHOMEOSTASISAnnual Review of Nutrition, 2002
- Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol- 4-yl)ethoxy]phenoxy}propionic Acids: A New Class of Dual PPARα/γ AgonistsJournal of Medicinal Chemistry, 2001
- Pharmacologic Therapy for Type 2 Diabetes MellitusAnnals of Internal Medicine, 1999